Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA?-Reference-Cited by-同舟云学术

Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA?

Published:2020-06-02 Issue:9 Volume:26 Page:1315-1318
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Hashash Jana G¹,Abou Fadel Carla²,Hosni Mohammad¹,Hassoun Lara¹,Kanafani Zeina³,Regueiro Miguel D⁴

Affiliation:

1. Division of Gastroenterology, American University of Beirut, Beirut, Lebanon

2. Bellevue Medical Center, Beirut, Lebanon

3. Division of Infectious Diseases, American University of Beirut, Beirut, Lebanon

4. Division of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, OH, USA

Abstract

Abstract The use of biological agents for the treatment of chronic inflammatory conditions such as inflammatory bowel diseases (IBD) has been on the rise.1,2 Current biological therapies include antitumor necrosis factor-α (anti-TNF-α), anti-interleukin-12/23, and anti-integrin agents. Before initiation of biological drugs, screening for Mycobacterium tuberculosis infection is required to avoid reactivation or worsening of disease after immunosuppression. It has been shown that anti-TNF-α treated patients have a 14-fold increased risk of tuberculosis (TB) infection/reactivation compared with healthy controls.3 The methods for screening for TB have evolved over time and vary from region to region.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/26/9/1315/33669934/izaa139.pdf

Reference34 articles.

1. Tumor necrosis factor inhibitors–state of knowledge;Lis;Archives of medical science: AMS,2014

2. Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing Anti-TNF treatment: a descriptive study on the GETAID Cohort;Abitbol;J Crohns Colitis.,2016

3. A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune-mediated inflammatory diseases;Lee;J Crohns Colitis.,2018

4. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease;Rahier;J Crohns Colitis.,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuberculin skin test result detection method based on CSN-II and improved OTSU method;Measurement;2024-04

2. Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies;Inflammatory Bowel Diseases;2023-07-14

3. Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease;Saudi Journal of Gastroenterology;2022-11-21

4. Repeatability of QuantiFERON-TB gold plus testing utilizing microparticle chemiluminescence;Journal of Immunological Methods;2022-10

5. Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression;Jornal Brasileiro de Pneumologia;2022-04-30